Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 5
1993 9
1994 12
1995 8
1996 9
1997 12
1998 18
1999 25
2000 26
2001 27
2002 29
2003 28
2004 40
2005 37
2006 28
2007 36
2008 32
2009 34
2010 43
2011 35
2012 26
2013 23
2014 31
2015 29
2016 32
2017 17
2018 27
2019 16
2020 27
2021 42
2022 34
2023 15

Text availability

Article attribute

Article type

Publication date

Search Results

749 results

Results by year

Filters applied: . Clear all
Page 1
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R. Cacabelos R. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole, …
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomati …
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Liao X, et al. Neurol Sci. 2020 Aug;41(8):2045-2054. doi: 10.1007/s10072-020-04303-x. Epub 2020 Mar 11. Neurol Sci. 2020. PMID: 32162166 Review.
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson's disease (PD) still need to be assessed. ...PubMed, Embase, the Cochrane Library, and th …
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and …
Entacapone alleviates acute kidney injury by inhibiting ferroptosis.
Yang J, Sun X, Huang N, Li P, He J, Jiang L, Zhang X, Han S, Xin H. Yang J, et al. FASEB J. 2022 Jul;36(7):e22399. doi: 10.1096/fj.202200241RR. FASEB J. 2022. PMID: 35691001
We demonstrated that entacapone prevents renal I/R injury by inhibiting ferroptosis. Compared with a sham group, entacapone treatment mitigated I/R-induced pathological alterations, improved renal function, and inhibited ferroptosis. ...Entacapone may serve a …
We demonstrated that entacapone prevents renal I/R injury by inhibiting ferroptosis. Compared with a sham group, entacapone tr …
Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1.
Peng S, Xiao W, Ju D, Sun B, Hou N, Liu Q, Wang Y, Zhao H, Gao C, Zhang S, Cao R, Li P, Huang H, Ma Y, Wang Y, Lai W, Ma Z, Zhang W, Huang S, Wang H, Zhang Z, Zhao L, Cai T, Zhao YL, Wang F, Nie Y, Zhi G, Yang YG, Zhang EE, Huang N. Peng S, et al. Sci Transl Med. 2019 Apr 17;11(488):eaau7116. doi: 10.1126/scitranslmed.aau7116. Sci Transl Med. 2019. PMID: 30996080
Here, we used a structure-based virtual screening of U.S. Food and Drug Administration-approved drugs to identify entacapone as a potential FTO inhibitor. Using structural and biochemical studies, we showed that entacapone directly bound to FTO and inhibited FTO act …
Here, we used a structure-based virtual screening of U.S. Food and Drug Administration-approved drugs to identify entacapone as a pot …
Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance.
Nyholm D, Jost WH. Nyholm D, et al. Ther Adv Neurol Disord. 2022 Jun 26;15:17562864221108018. doi: 10.1177/17562864221108018. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35785401 Free PMC article. Review.
At this point, patients may wish to consider a device-aided therapy (DAT) that provides continuous dopaminergic stimulation to help overcome these issues. Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed DAT option. ...In terms of clini …
At this point, patients may wish to consider a device-aided therapy (DAT) that provides continuous dopaminergic stimulation to help overcome …
Entacapone.
Chong BS, Mersfelder TL. Chong BS, et al. Ann Pharmacother. 2000 Sep;34(9):1056-65. doi: 10.1345/aph.19328. Ann Pharmacother. 2000. PMID: 10981253 Review.
Entacapone in combination with levodopa/dopa decarboxylase inhibitor has been shown to increase the AUC of levodopa, which leads to less fluctuation of levodopa plasma concentrations. ...The recommended dosage of entacapone is 200 mg administered orally with each do …
Entacapone in combination with levodopa/dopa decarboxylase inhibitor has been shown to increase the AUC of levodopa, which leads to l …
Targeted Inhibition of FTO Demethylase Protects Mice Against LPS-Induced Septic Shock by Suppressing NLRP3 Inflammasome.
Luo J, Wang F, Sun F, Yue T, Zhou Q, Yang C, Rong S, Yang P, Xiong F, Yu Q, Zhang S, Wang CY, Li J. Luo J, et al. Front Immunol. 2021 May 4;12:663295. doi: 10.3389/fimmu.2021.663295. eCollection 2021. Front Immunol. 2021. PMID: 34017338 Free PMC article.
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrophage activation, reduced the tissue damage and improved survival in a mouse model of LPS-induced endotoxic shock. ...
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrop …
Entacapone.
Müller T. Müller T. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Expert Opin Drug Metab Toxicol. 2010. PMID: 20572781 Review.
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs. ...
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs …
Colite lymphocytaire associée à l’entacapone.
Rodrigues DM, Hsieh E, Bernstein M, Juurlink DN. Rodrigues DM, et al. CMAJ. 2023 Jan 23;195(3):E132-E135. doi: 10.1503/cmaj.220680-f. CMAJ. 2023. PMID: 36690360 Free PMC article. French. No abstract available.
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Warren Olanow C, et al. Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29. Mov Disord. 2013. PMID: 23630119 Clinical Trial.
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the …
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy …
749 results